Target
TLR7
4 abstracts
Abstract
TransCon IL-2 β/γ alone or in combination with pembrolizumab, standard of care chemotherapy or TransCon TLR7/8 agonist in advanced/metastatic solid tumors: Updated results of the phase 1/2 IL Believe study.Org: Gabrail Cancer and Research Center, Cancer Research South Australia,
Abstract
Phase 2 study of novel HER2-targeting, TLR7/8 immune-stimulating antibody conjugate (ISAC) BDC-1001 (trastuzumab imbotolimod) +/- pertuzumab (P) in patients (pts) with HER2-positive metastatic breast cancer (MBC) previously treated with trastuzumab deruxtecan (T-DXd).Org: Stanford University Medical Center, University of Miami Health System, Stanford University School of Medicine, Medical Oncology Department, Ramón y Cajal University Hospital, Levine Cancer Institute, Atrium Heath,
Abstract
A phase 2 study of EIK1001, a Toll-like receptor 7/8 (TLR7/8) agonist, in combination with pembrolizumab and chemotherapy in patients with stage 4 non-small cell lung cancer.Org: White Plains Hospital, Center for Cancer Care, White Plains, NY, Medstar Franklin Square Medical Center,
Abstract
T cell redirecting and TLR7/8 agonist encapsulated liposomes targeting HER2+ tumors: Preclinical efficacy, pharmacokinetics and safety evaluations.Org: Hangzhou Highfield Biopharmaceuticals Inc., Clinical Trial Center and Department of Epidemiology - IRCCS Ospedale Policlinico San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy, National Cancer Center Hospital East, Kashiwa, Japan, National Clinical Research Center for Cancer, Cancer Hospital of Chinese Academy of Medical Sciences,